Tower Research Capital LLC (Trc) Gt Biopharma, Inc. Transaction History

Tower Research Capital LLC (Trc)

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.22 - $0.28 $84 - $107	-383 Reduced 1.9%	19,775 $5,000
Q3 2023 Nov 14, 2023	BUY	$0.24 - $0.35 $80 - $117	335 Added 1.69%	20,158 $4,000
Q2 2023 Aug 14, 2023	SELL	$0.22 - $0.55 $1,890 - $4,725	-8,592 Reduced 30.24%	19,823 $6,000
Q1 2023 May 09, 2023	BUY	$0.46 - $1.05 $5,976 - $13,641	12,992 Added 84.24%	28,415 $16,000
Q4 2022 Feb 10, 2023	BUY	$0.89 - $58.2 $8,943 - $584,851	10,049 Added 186.99%	15,423 $14,000
Q3 2022 Nov 10, 2022	BUY	$1.81 - $56.1 $3,046 - $94,416	1,683 Added 45.6%	5,374 $9,000
Q2 2022 Aug 15, 2022	BUY	$1.64 - $3.11 $754 - $1,430	460 Added 14.24%	3,691 $11,000
Q1 2022 May 12, 2022	SELL	$2.6 - $3.3 $1,708 - $2,168	-657 Reduced 16.9%	3,231 $9,000
Q4 2021 Feb 14, 2022	BUY	$3.05 - $7.08 $1,445 - $3,355	474 Added 13.88%	3,888 $12,000
Q3 2021 Nov 15, 2021	BUY	$6.68 - $15.26 $20,968 - $47,901	3,139 Added 1141.45%	3,414 $23,000
Q2 2021 Aug 16, 2021	SELL	$7.19 - $18.96 $7,729 - $20,382	-1,075 Reduced 79.63%	275 $4,000
Q1 2021 May 17, 2021	BUY	$4.4 - $8.84 $5,940 - $11,934	1,350 New	1,350 $9,000

564

Ticker GTBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,557,700
Market Cap $81.7M
Description
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate th...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.